跳至主要内容
临床试验/NCT01724242
NCT01724242撤回2 期

Vaginal DHEA to Ease Vaginal Dryness in Women With a Contraindication to Estrogen Therapy

Hadassah Medical Organization1 个研究点 分布在 1 个国家开始时间: 2013年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
试验地点
1
主要终点
improvement in vaginal dryness

研究概览

简要总结

There does not appear to be a consensus regarding the treatment of vaginal dryness in women who have a contraindication to the use of estrogen products. DHEA, when used locally, may improve the symptoms of vaginal dryness due to its chemical properties.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 55 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • women post menopausal aged 35-55, suffering from vaginal dryness, secondary to chemotherapy for breast cancer, within 5 years of diagnosis. Follicle Stimulating Hormone and Estradiol levels in the post menopausal range are needed.

排除标准

  • women using products to alleviate vaginal dryness.
  • women taking medication for urinary incontinence
  • women not sexually active, for other reasons.

研究组 & 干预措施

Vaginal DHEA

Experimental

Vaginal DHEA 0.5%(6.5mg)inserted nightly

干预措施: Vaginal DHEA (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

improvement in vaginal dryness

时间窗: 12 weeks

次要结局

  • improvement in urinary incontinence(12 weeks)
  • improvement in sexual satisfaction(12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验